NCT06430827尚未招募2 期
Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma.
Ba Yi1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年6月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient had good compliance, could understand the research process of this study, and signed a written informed consent.
- •Age ≥18 years.
- •Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer).
- •Subjects who had received gemcitabine prior first-line therapy and had not received fluorouracil drugs.
- •Subjects who have progressed after receiving previous first-line therapy, relapse within 6 months after the end of (neo) adjuvant therapy is considered as first-line therapy failure.
- •Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
- •ECOG (Eastern Cooperative Oncology Group) performance status of 0-
- •Has a life expectancy of greater than 3 months.
- •Appropriate organ function is defined as follows: (Hematology and blood biochemistry tests must be completed within 14 days prior to enrollment, and the following criteria are met):
- •ANC ≥1.5×10^9/L
- •PLT ≥100×10^9/L
- •total bilirubin ≤1.5 x ULN
- •ALT/AST ≤ 2.5 x ULN; When there is liver metastasis, ALT/AST ≤ 5 x ULN
- •Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr) ≥50mL/min (according to Cockcroft-Gault fórmula)
- •Coagulation function: prothrombin time (PT), activated partial thromboplastin time (APTT) and international standardized ratio (INR) ≤1.5×ULN
- •Patients with biliary obstruction should receive adequate biliary drainage.
- •Adverse reactions caused by previous treatment must be restored to grade 1 or baseline according to CTCAE5.0 (except for toxicity such as alopecias, grade 2 and below peripheral neuropathy, which can be included after the investigator determines that there is no safety risk).
- •non-pregnant or lactating female; Effective contraception should be used by female/Male of childbearing age during the study period and for 6 months after the end of study treatment.
- •There were no contraindications for the use of irinotecan liposomes and capecitabine.
排除标准
- •Patients who have had other malignant tumors within the previous 5 years (except cured carcinoma in situ and skin basal cell carcinoma).
- •Uncontrolled pleural effusion or ascites.
- •Any known brain or meningeal metastases.
- •Subjects were co-administering a potent CYP3A4 inducer within 3 weeks prior to first dosing, or a potent CYP3A4 inhibitor or a potent UGT1A1 inhibitor within 3 weeks prior to first dosing.
- •Subjects underwent large organ surgery (except needle biopsy, central venous catheterization, port catheterization, stenting for relief of biliary obstruction, percutaneous hepatobiliary drainage, and cholecystostomy) or an elective surgical program within 4 weeks before the first dose of the study drug.
- •Active, uncontrolled bacterial, viral, or fungal infections with systemic treatment, defined as persistent signs/symptoms associated with infection that do not go away despite the use of appropriate antibiotics, antiviral therapy, and/or other treatment, including patients with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- •Patients who are known to have dihydropyridine dehydrogenase (low activity) or deficiency.
- •There are serious concomitant diseases: such as uncontrolled diabetes after hypoglycemic drug treatment, uncontrolled hypertension, serious cardiovascular and cerebrovascular disease, kidney failure, liver failure, uncontrolled epilepsy, central nervous system disease or mental disorder history, clear gastrointestinal bleeding tendency, intestinal paralysis, intestinal obstruction, etc.
- •Grade 1 diarrhea with an increase in the number of stools > 4 times per day compared to baseline; The moderate and severe effluents from stoma increased; Limited activities of daily living with the aid of tools or even self-rational activities of daily living; Life-threatening; Need urgent medical attention.
- •Had participated in other clinical investigators within 4 weeks before enrollment.
- •Unsuitable for participation in the trial by the investigator assessed.
研究组 & 干预措施
Experimental
Experimental
Patients will receive irinotecan hydrochloride liposome injection combined with Capecitabine therapy in a 2-week treatment cycle.
干预措施: irinotecan hydrochloride liposome injection (Drug)
Experimental
Experimental
Patients will receive irinotecan hydrochloride liposome injection combined with Capecitabine therapy in a 2-week treatment cycle.
干预措施: Capecitabine (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: baseline up to approximately 6 months
To evaluate the efficacy of anti-tumor
次要结局
- Objective response rate (ORR)(baseline up to approximately 6 months)
- Overall survival (OS)(baseline up to approximately 12 months)
- Quality of life (QoL)(baseline up to approximately 12 months)
研究者
Ba Yi
Director
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract CarcinomaBiliary Tract CarcinomaNCT06463548Yunpeng Liu30
招募中
不适用
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic CancerAdjuvant TherapyPancreatic CancerNCT06361316Kuirong Jiang53
已完成
3 期
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine TreatmentMetastatic Adenocarcinoma of the PancreasNCT04083235Ipsen770
已完成
3 期
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic CancerSecond-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based TherapyNCT05074589Jiangsu HengRui Medicine Co., Ltd.298
招募中
2 期
Liposomal Irinotecan and Apatinib in ES-SCLCSmall Cell Lung Cancer Extensive StageNCT06749691Second Affiliated Hospital, School of Medicine, Zhejiang University30